3/18
02:52 pm
optn
OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/18
02:51 pm
optn
OptiNose, Inc. (NASDAQ: OPTN) had its price target raised by analysts at Lake Street Capital from $3.00 to $4.00. They now have a "buy" rating on the stock.
Low
Report
OptiNose, Inc. (NASDAQ: OPTN) had its price target raised by analysts at Lake Street Capital from $3.00 to $4.00. They now have a "buy" rating on the stock.
3/16
08:44 am
optn
OptiNose granted FDA nod to expand labeling for sinusitis therapy [Seeking Alpha]
Low
Report
OptiNose granted FDA nod to expand labeling for sinusitis therapy [Seeking Alpha]
3/15
03:43 pm
optn
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps [Yahoo! Finance]
Neutral
Report
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps [Yahoo! Finance]
3/15
03:34 pm
optn
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Neutral
Report
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
3/11
08:12 am
optn
OptiNose, Inc. (NASDAQ: OPTN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $5.00 price target on the stock.
High
Report
OptiNose, Inc. (NASDAQ: OPTN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $5.00 price target on the stock.
3/10
08:52 am
optn
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results [Yahoo! Finance]
High
Report
US$3.00: That's What Analysts Think OptiNose, Inc. (NASDAQ:OPTN) Is Worth After Its Latest Results [Yahoo! Finance]
3/8
10:07 am
optn
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/8
06:12 am
optn
OptiNose Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
OptiNose Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
3/7
02:12 pm
optn
OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ... [Yahoo! Finance]
Neutral
Report
OptiNose Inc (OPTN) Reports Decline in 2023 Revenue Amidst Preparations for Potential XHANCE ... [Yahoo! Finance]
3/7
09:49 am
optn
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]
3/7
07:16 am
optn
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights [Yahoo! Finance]
Low
Report
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights [Yahoo! Finance]
3/7
07:00 am
optn
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Low
Report
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
2/29
04:40 pm
optn
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Medium
Report
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
2/15
05:48 am
optn
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Low
Report
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock? [Yahoo! Finance]
1/18
12:09 pm
optn
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice [Yahoo! Finance]
Low
Report
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice [Yahoo! Finance]
1/18
12:00 pm
optn
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Low
Report
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice